This inventor holds 5 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 3 EPO patents. Top assignee: Gilead Sciences, Inc.. Active years: 2022-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022-2025
Title: Dietrich P Steinhuebel: Innovator in Cancer Treatment
Introduction
Dietrich P Steinhuebel is a prominent inventor based in San Francisco, CA. He has made significant contributions to the field of cancer treatment through his innovative work in developing MCL1 inhibitors. With a total of five patents to his name, Steinhuebel is recognized for his expertise and dedication to advancing medical science.
Latest Patents
Steinhuebel's latest patents focus on processes and intermediates for preparing MCL1 inhibitors. The first patent provides methods for preparing MCL1 inhibitors or a salt thereof, along with related key intermediates. The second patent relates to methods and intermediates for the synthesis of certain compounds that inhibit MCL1, specifically for use in the treatment of cancers. These patents highlight his commitment to finding effective solutions for challenging medical conditions.
Career Highlights
Throughout his career, Dietrich P Steinhuebel has been associated with Gilead Sciences, Inc., a leading biopharmaceutical company. His work at Gilead has allowed him to collaborate with other talented professionals in the field, further enhancing his contributions to cancer research and treatment.
Collaborations
Steinhuebel has worked alongside notable colleagues such as Darryl D Dixon and Michael A Ischay. These collaborations have fostered a productive environment for innovation and have led to significant advancements in the development
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile